No Data
China National Pharmaceutical Group Corporation (600056.SH): Appoints Zhang Lin as Secretary to the Board of Directors
Gelonghui, September 7 | China National Pharmaceutical Group (600056.SH) announced that on September 7, 2026, the company convened the 7th meeting of its 10th Board of Directors, at which it
Day One of the 2026 National Reimbursement Drug List Negotiations: Representatives from Multiple Companies Display Visible Joy as Traditional Chinese Medicine and Chronic Disease Drugs Take Center Stage
The annual national medical insurance catalog negotiations have once again entered the stage of on-site bargaining.
China National Medicines (600056.SH): Yuan Jinghua Resigns as Secretary to the Board of Directors
Gelonghui, September 1 — China National Pharmaceutical Group Corporation (600056.SH) announced that its Board of Directors recently received a written resignation letter from Mr. Yuan Jinghua, the Company's Secretary to the Board of Directors. Due to work adjustments, Mr. Yuan has applied to resign from his position as Secretary to the Board of Directors and will continue to serve as Deputy Chief Economist at the Company. During the vacancy in the position of Secretary to the Board of Directors, the Chairman of the Board shall perform the duties thereof. In accordance with relevant regulations such as the "Rules for the Supervision of Secretaries to the Boards of Directors of Listed Companies," the Chairman of the Board shall act on behalf of the Secretary to the Board of Directors during the vacancy. The Company will complete the selection and appointment of a new Secretary to the Board of Directors as soon as possible in accordance with relevant regulations.
China Pharmaceutical: Summary of the Semi-Annual Report for 2026
China Pharmaceutical: Full Text of the 2026 Semi-Annual Report
Guangdong True Health Strikes State-Backed Oncology Robotics Pact in Northeast China